MARK DANIEL: Open Payments
NPI 1700883659 · ELBERTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,580 in 83 payments from 20 companies in 2025. Trend: 2023 $1,792 · 2024 $1,915 · 2025 $1,580
Food & beverage: $1,580
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $227 |
| Axsome Therapeutics, Inc. | 9 | $180 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $144 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $114 |
| AstraZeneca Pharmaceuticals LP | 6 | $105 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $103 |
| Novo Nordisk Inc | 6 | $99 |
| PFIZER INC. | 5 | $97 |
| Exact Sciences Corporation | 4 | $84 |
| Lilly USA, LLC | 4 | $66 |
Products named: REXULTI, Auvelity, CAPLYTA, JARDIANCE, Kerendia, Ozempic, MOUNJARO, TZIELD.
Industry payments across GA — which companies pay providers there.
